| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13G · 3 securities · passive | ||||||
|
Neumora Therapeutics, Inc.
13G/A
NMRA · 640979100
|
3.1% |
5/15/2026
Event 3/31/2026
|
||||
| K2 HealthVentures Equity Trust LLC | 3.1% | |||||
| Parag Shah | 3.1% | |||||
| Anup Arora | 3.1% | |||||
|
Alto Neuroscience, Inc.
13G/A
ANRO · 02157Q109
|
2.4% |
2/17/2026
Event 12/31/2025
|
||||
| K2 HealthVentures Equity Trust LLC | 2.4% | |||||
| Parag Shah | 2.4% | |||||
| Anup Arora | 2.4% | |||||
|
TScan Therapeutics, Inc.
13G/A
TCRX · 89854M101
|
6.9% |
2/14/2025
Event 12/31/2024
|
||||
| K2 HealthVentures Equity Trust LLC | 6.9% | |||||
| Parag Shah | 6.9% | |||||
| Anup Arora | 6.9% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.